Rui Salvador

Dr. Rui Salvador


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RSRui Salvador
Rui Salvador
CMCarla Moutinho
Carla Moutinho
CSCarla Alexandra Lopes Andrade de Sousa e Silva
Carla Alexandra Lopes Andrade de Sousa e Silva
AVAna Ferreira Vinha
Ana Ferreira Vinha
Márcia CarvalhoMárcia Carvalho
Márcia Carvalho
CMCarla Matos
Carla Matos
This review addresses the role of semaglutide (SMG), a GLP-1 receptor agonist, in the treatment of obesity and its related comorbidities. Originally developed for type 2 diabetes (DM2), SMG has shown significant efficacy in weight reduction, with superior results compared to other treatments in the same class. Its effects include appetite suppression, increased satiety, and improvements in cardiovascular, renal, and metabolic parameters. Studies such as SUSTAIN, PIONEER, and STEP highlight its superiority compared to other GLP-1 receptor agonists and anti-obesity drugs. The oral formulation showed promising initial results, with higher doses (50 mg) showing weight losses comparable to those of subcutaneous administration. Despite its benefits, there are challenges, such as weight regain after cessation of treatment, gastrointestinal adverse effects, and variability of response. Future studies should explore strategies to mitigate these effects, identify predictive factors of efficacy, and expand therapeutic indications to other conditions related to obesity and insulin resistance. The constant innovation in this class of drugs reinforces the potential of SMG to transform treatment protocols for chronic weight-related diseases.